Literature DB >> 24083719

Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line.

Chuan-Kun Wang1, Xi-Dong Yu, Qiang Li, Gang Xie, Yue Teng.   

Abstract

Choroquine (CQ) and valproic acid (VPA) have been extensively studied for biological effects. Here, we focused on efficacy of combined CQ and VPA on osteosarcoma cell lines. Viability of osteosarcoma cell lines (U20S and HOS) was analyzed by MTT assay. Apoptotic assays and colony formation assays were also applied. ROS generation and Western Blotting were performed to determine the mechanism of CQ and VPA combination in the process of apoptosis. The viability of different osteosarcoma cell lines significantly decreased after CQ and VPA combination treatment compared with either drug used alone, and apoptosis was increased significantly. ROS generation was triggered leading to expression of apoptosis related genes being increased and of anti- apoptotic related genes being decreased. From our data shown here, CQ and VPA combination treatment in vitro enhanced cytotoxicy to osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24083719     DOI: 10.7314/apjcp.2013.14.8.4651

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

Review 1.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

2.  Reactive Oxygen Species-Mediated Mitochondrial Dysfunction Triggers Sodium Valproate-Induced Cytotoxicity in Human Colorectal Adenocarcinoma Cells.

Authors:  Bondada Venkata Mani Anirudh; Devaraj Ezhilarasan
Journal:  J Gastrointest Cancer       Date:  2021-09

3.  Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.

Authors:  Chuhai Xie; Boyi Wu; Binwei Chen; Qunwei Shi; Jianhong Guo; Ziwen Fan; Yan Huang
Journal:  Onco Targets Ther       Date:  2016-07-04       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.